On the 29th, Vime Co., Ltd. announced that it has signed an integrated distribution partnership for the European continent with Laboratoires FILLMED, a global medical aesthetics company headquartered in Paris, Europe.
Founded in Paris, France in 1978, Philmed has a variety of products, including the growth factor complex 'NCTF 135 HA', hyaluronic acid filler (ArtFiller), and sterile injection needles (Nanosoft), and is currently sold in over 80 countries worldwide and approximately 35 countries in Europe.
Vime owns the "Juvelook" brand, a medical device containing PDLLA, which promotes autologous collagen formation. Its natural and safe cosmetic effects are gaining recognition. Furthermore, Vime consistently participates in international conferences and exhibitions (IMCAS, AMWC, etc.) to increase brand awareness, and won the "Best Injectable of Skin Revitalization" award at the 23rd AMWC held in March of this year.
Through this partnership, both companies plan to leverage Philmed's European sales and marketing network and experience to strengthen Juvelook's presence in the European market. Localized product supply and marketing strategies are expected to provide customized services tailored to each country's unique characteristics.
A Baim representative stated, "Leveraging Philmed's infrastructure and expertise, we will quickly establish 'Juvelook''s credibility in the European market and accelerate its growth. This agreement is the first step toward establishing a global medical aesthetics platform." They added, "We will continue to strive to create a strong brand presence in the European market."
- See more related articles
You must be logged in to post a comment.